A photo of Daniel Starczynowski.

Daniel T. Starczynowski, PhD

  • Member, Division of Experimental Hematology & Cancer Biology
  • Co-Leader, Hematologic Malignancies Program, Cancer and Blood Diseases Institute 
    Co-Chief Scientific Officer, Innovation Ventures
    Katherine Stewart Waters Endowed Chair of Hematologic Malignancies
  • Professor, UC Department of Pediatrics

About

Biography

Daniel T. Starczynowski, PhD, received his PhD in molecular biology from Boston University. He studied the NF-kB family of transcription factors and their role in B-cell lymphomas. During his postdoctoral fellowship at the BC Cancer Research Center, Dr. Starczynowski identified and characterized novel candidate genes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Following his postdoctoral training, Dr. Starczynowski joined the faculty at Cincinnati Children’s Hospital Medical Center and at the University of Cincinnati as an Assistant Professor. Dr. Starczynowski’s laboratory investigates the molecular and cellular basis of hematologic malignancies with the goal to advance novel therapeutic strategies.

BS: Fairleigh Dickinson University, Teaneck, NJ, 2000.

PhD: Boston University, Boston, MA, 2006.

Postdoctoral Fellow: University of British Columbia/BC Cancer Research Centre, Vancouver, Canada, 2010.

Research Areas

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Inflammation and Tolerance

Publications

IKAROS and MENIN in synergy in AML. Jones, LM; Starczynowski, DT. 2022; 3:528-529.

Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Barreyro, L; Sampson, AM; Ishikawa, C; Hueneman, KM; Choi, K; Pujato, MA; Chutipongtanate, S; Wyder, M; Haffey, WD; O'Brien, E; et al. Science Translational Medicine. 2022; 14.

Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Azhar, M; Kincaid, Z; Kesarwani, M; Ahmed, A; Wunderlich, M; Latif, T; Starczynowski, D; Azam, M. Blood Advances. 2022; 6:1186-1192.

TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Muto, T; Guillamot, M; Yeung, J; Fang, J; Bennett, J; Nadorp, B; Lasry, A; Redondo, LZ; Choi, K; Gong, Y; et al. Cell Stem Cell. 2022; 29:298-314.e9.

The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Niederkorn, M; Ishikawa, C; M. Hueneman, K; Bartram, J; Stepanchick, E; R. Bennett, J; E. Culver-Cochran, A; Bolanos, LC; Uible, E; Choi, K; et al. Leukemia. 2022; 36:438-451.

Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes. Aoyagi, Y; Hayashi, Y; Harada, Y; Choi, K; Matsunuma, N; Sadato, D; Maemoto, Y; Ito, A; Yanagi, S; Starczynowski, DT; et al. Cancer Discovery. 2022; 12:250-269.

IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Bennett, J; Starczynowski, DT. Current Opinion in Hematology. 2022; 29:8-19.

Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML. Azhar, M; Kincaid, Z; Kesarwani, M; Wunderlich, M; Latif, T; Starczynowski, D; Azam, M. Blood. 2021; 138:206-206.

Heterozygous Mutations in DDX41 Cause Erythroid Progenitor Cell Defects. Chlon, TM; Stepanchick, E; Sulentic, A; Hueneman, K; Starczynowski, D. Blood. 2021; 138:148-148.

Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Chlon, TM; Stepanchick, E; Hershberger, CE; Daniels, NJ; Hueneman, KM; Kuenzi Davis, A; Choi, K; Zheng, Y; Gurnari, C; Haferlach, T; et al. Cell Stem Cell. 2021; 28:1966-1981.e6.

From the Blog